With Fundraising, A Track Record Matters: GeoVax’s David Dodd2/1/2023
Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.
Why Takeda Is Focusing So Much On Plasma-Derived Therapies2/1/2023
Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
Verve Therapeutics: How To Build A Gene Editing Biotech1/3/2023
Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.
Peter Marks: Prioritizing Better Communication And Faster Product Reviews1/3/2023
In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.
The Next Big Thing1/3/2023
Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?
Executive Outlook: Crafting New Solutions For Persisting Problems12/1/2022
Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).
Will The Finance And Funding Pendulum Swing Back To Black In 2023?12/1/2022
Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.
Building New Solutions For 2023 In Manufacturing And Supply Chain12/1/2022
In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.
Only The Creative Survive12/1/2022
Looking through my 2022 coverage areas, and in reading through my colleagues’ outlook articles, what was most compelling to me were not necessarily the specific issues raised, but how leadership approached those issues to create solutions.